Neena Bitritto-Garg
Stock Analyst at Deutsche Bank
(4.10)
# 526
Out of 4,667 analysts
82
Total ratings
43.33%
Success rate
17.12%
Average return
Main Sectors:
Stocks Rated by Neena Bitritto-Garg
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ROIV Roivant Sciences | Maintains: Buy | $14 → $15 | $11.49 | +30.55% | 5 | Apr 3, 2024 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Buy | $36 → $8 | $5.23 | +52.96% | 7 | Mar 11, 2024 | |
| ACAD ACADIA Pharmaceuticals | Downgrades: Hold | $25 | $16.27 | +53.66% | 15 | Dec 14, 2023 | |
| IMVT Immunovant | Initiates: Buy | $50 | $26.17 | +91.06% | 1 | Dec 12, 2023 | |
| NBIX Neurocrine Biosciences | Initiates: Buy | $136 | $123.29 | +10.31% | 7 | Dec 12, 2023 | |
| CMPS COMPASS Pathways | Initiates: Buy | $16 | $4.66 | +243.35% | 4 | Dec 12, 2023 | |
| PRTA Prothena Corporation | Initiates: Buy | $62 | $14.40 | +330.56% | 8 | Dec 12, 2023 | |
| ALEC Alector | Initiates: Buy | $12 | $3.64 | +230.12% | 6 | Dec 12, 2023 | |
| SAGE Sage Therapeutics | Initiates: Hold | $21 | $4.91 | +327.70% | 6 | Dec 12, 2023 | |
| SRPT Sarepta Therapeutics | Initiates: Buy | $109 | $110.86 | -1.68% | 3 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $2.37 | +237.55% | 1 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $17 | $59.77 | -71.56% | 3 | Mar 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $1.59 | +528.93% | 4 | Jan 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $5 | $0.51 | +873.33% | 3 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $6 | $5.79 | +3.63% | 5 | Aug 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $2.30 | +815.03% | 1 | Apr 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $23 | $72.67 | -68.35% | 1 | Jul 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $36 | $20.31 | +77.25% | 2 | Jul 11, 2017 |
Roivant Sciences
Apr 3, 2024
Maintains: Buy
Price Target: $14 → $15
Current: $11.49
Upside: +30.55%
Amylyx Pharmaceuticals
Mar 11, 2024
Maintains: Buy
Price Target: $36 → $8
Current: $5.23
Upside: +52.96%
ACADIA Pharmaceuticals
Dec 14, 2023
Downgrades: Hold
Price Target: $25
Current: $16.27
Upside: +53.66%
Immunovant
Dec 12, 2023
Initiates: Buy
Price Target: $50
Current: $26.17
Upside: +91.06%
Neurocrine Biosciences
Dec 12, 2023
Initiates: Buy
Price Target: $136
Current: $123.29
Upside: +10.31%
COMPASS Pathways
Dec 12, 2023
Initiates: Buy
Price Target: $16
Current: $4.66
Upside: +243.35%
Prothena Corporation
Dec 12, 2023
Initiates: Buy
Price Target: $62
Current: $14.40
Upside: +330.56%
Alector
Dec 12, 2023
Initiates: Buy
Price Target: $12
Current: $3.64
Upside: +230.12%
Sage Therapeutics
Dec 12, 2023
Initiates: Hold
Price Target: $21
Current: $4.91
Upside: +327.70%
Sarepta Therapeutics
Dec 12, 2023
Initiates: Buy
Price Target: $109
Current: $110.86
Upside: -1.68%
Dec 12, 2023
Initiates: Buy
Price Target: $8
Current: $2.37
Upside: +237.55%
Mar 9, 2023
Maintains: Buy
Price Target: $24 → $17
Current: $59.77
Upside: -71.56%
Jan 9, 2023
Maintains: Buy
Price Target: $20 → $10
Current: $1.59
Upside: +528.93%
Nov 11, 2022
Maintains: Buy
Price Target: $7 → $5
Current: $0.51
Upside: +873.33%
Aug 2, 2022
Downgrades: Sell
Price Target: $6
Current: $5.79
Upside: +3.63%
Apr 4, 2022
Initiates: Buy
Price Target: $21
Current: $2.30
Upside: +815.03%
Jul 11, 2017
Initiates: Outperform
Price Target: $23
Current: $72.67
Upside: -68.35%
Jul 11, 2017
Initiates: Outperform
Price Target: $36
Current: $20.31
Upside: +77.25%